LGALS3 and infarction: Moreover, Wang et al. (2023) showcased the therapeutic potential of targeting galectin-3 post-infarction [62], demonstrating its efficacy in attenuating progressive fibrosis by modulating inflammatory profibrotic pathways, thereby preserving diastolic function following myocardial infarction.